Agios Pharma (AGIO) Reports Q4 Loss of $1.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56
February 19, 2016 7:30 AM ESTLeerink Partners maintained a Market Perform rating on Agios Pharma (NASDAQ: AGIO), and cut the price target to $56.00 (from $62.00), following the company's 4Q earnings call. AGIO provided a number of incremental pipeline updates. Leerink sees the announced AG-348 and AG-519 data at EHA in June and... More
